Cargando…
DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay
Radiopharmaceuticals used for diagnosis or therapy induce DNA strand breaks, which may be detectable by single-cell gel electrophoresis (called comet assay). Blood was taken from patients before and at different time points after treatment with radiopharmaceuticals; blood cells were investigated by...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753384/ https://www.ncbi.nlm.nih.gov/pubmed/31107537 http://dx.doi.org/10.1093/mutage/gez007 |
_version_ | 1783452890998767616 |
---|---|
author | Schmeiser, Heinz H Muehlbauer, Karl-Rudolf Mier, Walter Baranski, Ann-Christin Neels, Oliver Dimitrakopoulou-Strauss, Antonia Schmezer, Peter Kratochwil, Clemens Bruchertseifer, Frank Morgenstern, Alfred Kopka, Klaus |
author_facet | Schmeiser, Heinz H Muehlbauer, Karl-Rudolf Mier, Walter Baranski, Ann-Christin Neels, Oliver Dimitrakopoulou-Strauss, Antonia Schmezer, Peter Kratochwil, Clemens Bruchertseifer, Frank Morgenstern, Alfred Kopka, Klaus |
author_sort | Schmeiser, Heinz H |
collection | PubMed |
description | Radiopharmaceuticals used for diagnosis or therapy induce DNA strand breaks, which may be detectable by single-cell gel electrophoresis (called comet assay). Blood was taken from patients before and at different time points after treatment with radiopharmaceuticals; blood cells were investigated by the comet assay using the percentage of DNA in the tail as the critical parameter. Whereas [(225)Ac]Ac-prostate-specific membrane antigen (PSMA)-617 alpha therapy showed no difference relative to the blood sample taken before treatment, beta therapy with [(177)Lu]Lu-PSMA-617 3 h post-injection revealed a small but significant increase in DNA strand breaks. In blood of patients who underwent positron emission tomography (PET) with either [(18)F]2-fluor-2-deoxy-D-glucose (FDG) or [(68)Ga]Ga-PSMA-11, an increase of DNA migration determined by the comet assay was not found when analysed at different time points (2–70 min) after intravenous tracer injection. Human whole blood was incubated with the targeted clinically relevant therapeutic radiopharmaceuticals [(225)Ac]Ac-PSMA-617, [(177)Lu]Lu-PSMA-617 and [(90)Y]Y-DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTA-TOC) at different activity concentrations (kBq/ml) for 5 days and then analysed by the comet assay. DNA damage increased with higher concentrations of all radiolabeled compounds tested. [(177)Lu]Lu-PSMA-617 caused higher blood cell radiotoxicity than equal activity concentrations of [(90)Y]Y-DOTA-TOC. Likewise, whole human blood was exposed to the positron emitters [(18)F]FDG and [(68)Ga]Ga-PSMA-11 in vitro for 24 h with activity concentrations ranging between 5 and 40 MBq/ml. The same activity concentration dependent elevated DNA migration was observed for both compounds although decay energies are different. This study demonstrated that the amount of DNA damage detected by the comet assay in whole human blood is similar among different positron emitters and divergent by a factor of 200 between alpha particles and beta radiation. |
format | Online Article Text |
id | pubmed-6753384 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-67533842019-09-25 DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay Schmeiser, Heinz H Muehlbauer, Karl-Rudolf Mier, Walter Baranski, Ann-Christin Neels, Oliver Dimitrakopoulou-Strauss, Antonia Schmezer, Peter Kratochwil, Clemens Bruchertseifer, Frank Morgenstern, Alfred Kopka, Klaus Mutagenesis Original Manuscripts Radiopharmaceuticals used for diagnosis or therapy induce DNA strand breaks, which may be detectable by single-cell gel electrophoresis (called comet assay). Blood was taken from patients before and at different time points after treatment with radiopharmaceuticals; blood cells were investigated by the comet assay using the percentage of DNA in the tail as the critical parameter. Whereas [(225)Ac]Ac-prostate-specific membrane antigen (PSMA)-617 alpha therapy showed no difference relative to the blood sample taken before treatment, beta therapy with [(177)Lu]Lu-PSMA-617 3 h post-injection revealed a small but significant increase in DNA strand breaks. In blood of patients who underwent positron emission tomography (PET) with either [(18)F]2-fluor-2-deoxy-D-glucose (FDG) or [(68)Ga]Ga-PSMA-11, an increase of DNA migration determined by the comet assay was not found when analysed at different time points (2–70 min) after intravenous tracer injection. Human whole blood was incubated with the targeted clinically relevant therapeutic radiopharmaceuticals [(225)Ac]Ac-PSMA-617, [(177)Lu]Lu-PSMA-617 and [(90)Y]Y-DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTA-TOC) at different activity concentrations (kBq/ml) for 5 days and then analysed by the comet assay. DNA damage increased with higher concentrations of all radiolabeled compounds tested. [(177)Lu]Lu-PSMA-617 caused higher blood cell radiotoxicity than equal activity concentrations of [(90)Y]Y-DOTA-TOC. Likewise, whole human blood was exposed to the positron emitters [(18)F]FDG and [(68)Ga]Ga-PSMA-11 in vitro for 24 h with activity concentrations ranging between 5 and 40 MBq/ml. The same activity concentration dependent elevated DNA migration was observed for both compounds although decay energies are different. This study demonstrated that the amount of DNA damage detected by the comet assay in whole human blood is similar among different positron emitters and divergent by a factor of 200 between alpha particles and beta radiation. Oxford University Press 2019-09 2019-05-20 /pmc/articles/PMC6753384/ /pubmed/31107537 http://dx.doi.org/10.1093/mutage/gez007 Text en © The Author 2019. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Manuscripts Schmeiser, Heinz H Muehlbauer, Karl-Rudolf Mier, Walter Baranski, Ann-Christin Neels, Oliver Dimitrakopoulou-Strauss, Antonia Schmezer, Peter Kratochwil, Clemens Bruchertseifer, Frank Morgenstern, Alfred Kopka, Klaus DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay |
title | DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay |
title_full | DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay |
title_fullStr | DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay |
title_full_unstemmed | DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay |
title_short | DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay |
title_sort | dna damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay |
topic | Original Manuscripts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753384/ https://www.ncbi.nlm.nih.gov/pubmed/31107537 http://dx.doi.org/10.1093/mutage/gez007 |
work_keys_str_mv | AT schmeiserheinzh dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay AT muehlbauerkarlrudolf dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay AT mierwalter dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay AT baranskiannchristin dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay AT neelsoliver dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay AT dimitrakopouloustraussantonia dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay AT schmezerpeter dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay AT kratochwilclemens dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay AT bruchertseiferfrank dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay AT morgensternalfred dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay AT kopkaklaus dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay |